PARP Clinical Trials in Beijing, Beijing Municipality
2 recruitingBeijing, Beijing Municipality, China
Showing 1–2 of 2 trials
Recruiting
Phase 1Phase 2
An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors
Advanced Solid TumorsPARP Inhibitor
Shanghai SciBrunch Therapeutics Co., Ltd.210 enrolled2 locationsNCT07359066
Recruiting
Not Applicable
Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
CDK4/6 InhibitorChemotherapeutic ToxicityTrastuzumab+5 more
Cancer Institute and Hospital, Chinese Academy of Medical Sciences148 enrolled1 locationNCT06197581